EGFR and non-small cell lung carcinoma: However, patients with NSCLC harboring EGFR exon 20 insertions (EGFR ex20ins) mutations, accounting for approximately 10% of all EGFR-positive NSCLC cases, usually show de novo resistance to the approved EGFR-TKIs (Yasuda et al., 2012).